Excessive vascular cell proliferation is an important component of pulmonary hypertension (PH). Perlecan is the major heparan sulfate (HS) proteoglycan in the vascular extracellular matrix. It binds growth factors, including FGF2, and either restricts or promotes cell proliferation. In this study, we have explored the effects of perlecan HS deficiency on pulmonary vascular development and in hypoxia-induced PH.
Introduction
Pulmonary hypertension (PH) is characterized by a progressive increase in pulmonary vascular resistance, which leads to right ventricular failure and death. Despite the increase in treatment options in recent years, the long-term outcome of patients with PH remains poor. 1 The aetiologies of PH are diverse, and PH can be divided into five groups according to the WHO classification. 2 Hypoxia is the major contributing factor in Group 3. 2 While acute hypoxia causes vasoconstriction, 3 chronic hypoxia results in vascular remodelling, including muscularization of distal non-muscular pulmonary arterioles, as well as medial and adventitial thickening of muscular vessels. 4, 5 Current therapy consists mainly of pulmonary vasodilators. However, recent studies have shown that anti-proliferative agents can reduce muscularization and thickening of vessels, improve haemodynamics, and reduce right ventricular hypertrophy. Modulators of growth factor signalling could therefore have a role as add-on therapy for PH. 6 The importance of growth factor pathways is well founded in the literature. PDGF-B regulates proliferation and migration of pulmonary artery smooth muscle cells (PASMCs) and plays a critical role in the progression of PH. 7 Increased expression and activation of PDGF receptor b (PDGFRb) has been shown in patients with PH and in animal models of hypoxia-induced PH. 8 Imatinib mesylate is a tyrosine kinase inhibitor that inhibits PDGFRb signalling and cell proliferation. 8 Recently, a phase III clinical trial reported improved right ventricular function in patients with advanced disease after 24 weeks of imatinib treatment as add-on therapy. 9 Imatinib is, however, not specific for the PDGF pathway, and it has not been approved for PH treatment because of serious side effects and frequent drug discontinuations. 10 Fibroblast growth factor-2 (FGF2) is another potent mitogen for smooth muscle cells (SMCs) that have been shown to accumulate in human pulmonary vascular lesions. The use of the pharmacological agent SU5402, a pan-FGF receptor inhibitor, successfully attenuates monocrotaline-induced PH in rats.
11 FGF2 has also recently been shown to mediate pericyte coverage of distal pulmonary arterioles in PH. 12 Growth factor signalling may be modulated by interactions with proteoglycans. Perlecan is a complex proteoglycan composed of a core protein ( 470 kDa) containing five globular domains and three GAG chains in the N-terminal and one in the C-terminal. 13 The GAG chains are mainly heparan sulfate (HS), but may also be chondroitin sulfate depending on cell type-specific post-translational modifications. 14, 15 Perlecan-null mutation is lethal with severe cardiac and neuromuscular disorders. 16, 17 In blood vessels, perlecan is deposited in the basement membranes underneath endothelial cells and around SMCs. 18 In the vascular wall, there are also cell membrane-bound HS proteoglycans (syndecans and glypicans), but perlecan is the major HS proteoglycan in the extracellular matrix. Perlecan HS has been shown to bind various growth factors, including FGF2 and PDGF-B, 19, 20 and thus serves as an important modulator of growth factor signalling. The HS chains may either sequester the growth factor and inhibit downstream signalling, or present the ligand to facilitate receptor activation. 21 To investigate the role of perlecan HS in pulmonary vascular development, and in the regulation of growth factor signalling in hypoxiainduced PH, we used a mouse strain that expresses perlecan deficient in HS (Hspg2 D3/D3 ). 22 The HS deficiency was generated through targeted deletion of the HS attachment sites in exon 3 (domain I). This results in loss of all three N-terminal HS chains. 22 The mice have been shown to develop spontaneous cataract, 22 impaired tumour angiogenesis, and wound healing. 23 Our group has previously shown that perlecan HS inhibits SMC proliferation in muscular arteries in the systemic circulation. In the carotid ligation model, the Hspg2
D3/D3
mice developed significantly more intimal hyperplasia compared with controls, possibly related to defective sequestration of FGF2 in the vascular extracellular matrix. 24 Previously, no apparent vascular pathology as an immediate consequence of the HS deficiency has been described in the Hspg2 D3/D3 mice, and the role of perlecan HS in the pulmonary circulation had not been explored. In this study, we hypothesized that perlecan HS can modulate growth factor -receptor interactions in vascular remodelling in PH. We show impaired pulmonary vascular development in mice expressing HS-deficient perlecan. When challenged with hypoxia, the PH is less severe in Hspg2 D3/D3 mice.
Methods
For some of the methods, a detailed description is available in Supplementary material online.
Animals
Hspg2 D3/D3 mice were generated as previously described by Rossi, et al. 
Exposure to chronic hypoxia
Female mice at 8 -11 weeks of age were divided into four experimental groups, wild-type normoxia, mutant normoxia, wild-type hypoxia, and mutant hypoxia. Hypoxic groups were kept in a ventilated hypoxic cabinet (10% O 2 , Coy Laboratory Products) for 3.5 days or 4 weeks. Normoxic groups were kept in room air.
Right ventricular systolic pressure
Under anaesthesia with 1.5% isoflurane, a micro catheter (Millar) was inserted into the right ventricle through the right external jugular vein. Right ventricular systolic pressure (RVSP) was recorded using a PowerLab w data acquisition system (ADInstruments).
In vivo mouse lung angiography
Under anaesthesia with 1.5% isoflurane, lung angiography was performed by an injection of contrast (Visipaque 270, GE Healthcare) into the right atrium. Live angiographic series (6 fps) in frontal projections were captured at least six times for each animal. Regions of interest were chosen in the right lower lobe, and contrast attenuation was measured and normalized to total pulmonary area. Details are provided in Supplementary material online.
Tissue preparation
After RVSP measurements and collection of heart and lung tissues, the right lung lobes were snap-frozen in liquid nitrogen for RNA and protein extraction. Left lungs were perfusion-fixed by infusion of 4% zinc-formaldehyde via the right ventricle and the trachea (perfusion pressure: 18 cmH 2 O), and further processed for paraffin sectioning. For the hearts, the right ventricle was separated from the left ventricle plus septum, and the samples were dried and weighed to obtain the right ventricle to left ventricle plus septum ratio [RV/(LV + S)].
Immunohistochemistry and IF
Enzyme-based probe-polymer systems were used for staining of paraffinembedded lung sections. Fluorochrome-conjugated secondary antibodies were used for IF of frozen sections. Details are provided in Supplementary material online.
Morphometric analysis and detection of proliferation
Double staining for von Willebrand factor and smooth muscle a-actin (a-SMA) was used for assessment of muscularization. For cell proliferation, Ki-67 staining was quantified by manual counting of positive and negative nuclei within the pulmonary vessels. Two proliferation indices were calculated: (i) total vascular cell proliferation index [(total Ki-67-positive nuclei in the entire vascular wall)/(total nuclei)] and (ii) pulmonary artery SMC proliferation index [(total Ki67-positive PASMC nuclei)/(PASMC nuclei)].
Proximity ligation assay
Duolink proximity ligation assay (PLA) was performed on paraffin-embedded lung sections following the manufacturer's instructions (Sigma-Aldrich). After blocking and primary antibody incubation with mouse anti-FGF2 antibody (5 mg/mL, clone bFM-2303, Millipore), and rabbit anti-perlecan antibody (1 mg/mL, sc-25848, Santa Cruz) overnight at 48C, PLA probes were added. Ligation and amplification were performed using the Duolink bright field detection kit. After conjugation with horseradish peroxidase, NovaRed substrate was used for detection.
2.9 FGF ligand and carbohydrate engagement assay 25 For ligand and carbohydrate engagement (LACE) assay on tissues, 5 mm paraffin-embedded lung sections were deparaffinized and rehydrated, followed by incubation in 0.1 M glycine in PBS for 30 min. To ensure that the observed binding was mediated by HS, control sections were treated with heparinase III (2 U/mL; Sigma-Aldrich) in heparinase buffer (50 mM HEPES, 50 mM NaOAc, 150 mM NaCl, 5 mM CaCl 2 , and 0.1% BSA, pH 6.8) at 378C for 4 h. All other sections were treated with heparinase buffer only. After blocking with 5% BSA in PBS, the sections were incubated with 2 mM recombinant human FGF2 and 2 mM human FGF receptor-1 (FGFR1) IIIc-Fc chimera (both from R&D systems) in blocking buffer overnight at 48C, and then washed with PBS, followed by incubation with the Cy3-conjugated anti-human Fc IgG secondary antibody (1 : 30, Sigma-Aldrich) at room temperature for 2 h. After washing with PBS and drying, the slides were mounted with fluorescence mounting medium (DAKO) and examined using a Nikon Optiphot-2 fluorescence microscope. For LACE on cell cultures, HRP-conjugated anti-human Fc IgG secondary antibody (1 : 5000, Sigma-Aldrich) was used instead. Details are provided in Supplementary material online.
RNA extraction and quantitative PCR
About 20 mg of lung tissue from each mouse was homogenized for RNA extraction. Quantitative real-time PCR was performed with Applied Biosystems' 7900HT system. Details are provided in Supplementary material online.
Protein extraction and western blot
Snap-frozen lungs were homogenized for protein extraction and western blot. The anti-FGFR1 antibody is specific to the C-terminus of FGFR1 protein and detected several bands as previously described. The antibody against phospho-FGFR1 has high specificity for phospho-Y654, the phosphorylation site essential for signalling. Details are provided in Supplementary material online.
Primary cell isolation and cell culture
Age-matched littermates of wild-type and Hspg2 D3/D3 mice were anaesthetized with isoflurane and euthanized by cervical dislocation. For each cell isolation, pulmonary arteries from six mice were pooled and enzyme digestion was used to obtain PASMCs as previously described. 24 Three different batches of cell isolates were used for all in vitro experiments. Details are provided in Supplementary material online.
Proliferation assay
Two methods were used for quantification of cell proliferation, BrdU incorporation (colorimetric ELISA assay, Roche), and manual cell counting. For hypoxia incubation, cells were cultured in an Invivo2 Hypoxia Workstation with 1% O 2 and 5% CO 2 (Ruskinn).
Adhesion assay
PASMCs from wild-type and mutant mice were allowed to adhere in 96-well plates coated with collagen IV, EHS laminin, or fibronectin. Details are provided in Supplementary material online. mice (n ¼ 6 per group) was analysed by Masson's trichrome and haematoxylin-eosin staining, and showed no signs of abnormalities in structure or collagen content in the Hspg2 D3/D3 mice ( Figure 1A ). Total vessel number per alveoli was equivalent to the wild-type (data not shown).
Statistics analysis
In contrast, double staining for endothelial cells and SMCs with von Willebrand factor and a-SMA revealed a lower percentage of a-SMA-positive pulmonary vessels in Hspg2 D3/D3 mice ( Figure 1B) . Western blot for three markers for SMC differentiation, a-SMA, myosin heavy chain 11, and SM22a, using aortic samples, showed no significant difference between wild-type and Hspg2 D3/D3 mice ( Figure 1C) , indicating that the lack of perlecan HS does not cause a general defect in SMC differentiation. The muscularization defect is likely to be caused by the cell number loss, and not by the change in cell protein content. In addition, confocal imaging confirmed loss of pericyte coverage in the distal pulmonary arterioles in Hspg2 D3/D3 mice ( Figure 1D ).
Peripheral perfusion defect demonstrated by in vivo pulmonary angiography
Defective muscularization of pulmonary vessels in the Hspg2 D3/D3 mice suggests a possible vascular developmental defect. Pulmonary angiograms showed perfusion defects in the peripheral parts of the lungs (Figure 2A) , and a significant reduction in contrast attenuation ( Figure 2B ), which indicates a possible arborization abnormality. The lumen diameter of pulmonary arteries was measured and normalized to the size of the thoracic aorta. In proximal pulmonary arteries up to third-degree branches, there were no detectable differences between Hspg2 D3/D3 and wild type mice (data not shown). This suggests that the possible arborization defect in Hspg2 D3/D3 lungs resides in more distal parts of the arterial tree.
Hypoxia induces perlecan expression
Perlecan mRNA isolated from whole lung was significantly increased after 3.5 days in hypoxia, and returned to baseline level after 4 weeks. These changes in perlecan mRNA expression in response to hypoxia were nearly identical between Hspg2 D3/D3 and wild-type mice ( Figure 3A) . Immunohistochemical analysis of lung sections showed a small amount of perlecan in the basement membranes of pulmonary vessels in normoxia ( Figure 3B ), which then increased significantly following 4 weeks of hypoxia ( Figure 3C ). No differences were observed between Hspg2 D3/D3 and wild type (not shown). and wild type, respectively ( Figure 4B ).
Reduction in hypoxia-induced vascular muscularization and SMC proliferation
Muscularization of intra-acinar vessels was quantified following double stainings for endothelial cells and SMCs as described by Schermuly et al. 8 Under normoxia, the proportion of non-muscularized vessels was significantly higher in the Hspg2 D3/D3 (76%) compared with the wild type (58%), and the proportion of partially and fully muscularized vessels was significantly lower in Hspg2 D3/D3 ( Figure 4C ). After 4 weeks of hypoxia, a significant increase in fully muscularized vessels was observed in both genotypes, and this increase was significantly less pronounced in Hspg2 D3/D3 ( Figure 4C ).
To evaluate cell proliferation, mice were exposed to 3.5 days of hypoxia. Previously published data have indicated that a peak in proliferation occurs between days 3 and 4.
26 Lung sections were double-stained for Ki-67 and a-SMA ( Figure 4D ). Hypoxia induced significant increases in proliferation of pulmonary vascular cells. However, the increased proliferation was significantly less in Hspg2 D3/D3 compared with wild type ( Figure 4E and F ).
Perlecan co-localization with FGF2 in pulmonary arteries
Double staining showed that perlecan and FGF2 are co-localized along the endothelium and in the extracellular matrix of pulmonary arteries ( Figure 5A ). In addition, PLA demonstrated positive amplification signals in pulmonary arteries, which confirmed that endogenous FGF2 and perlecan are within range for interaction with each other ( Figure 5B ).
Reduced HS -FGF2 -FGFR1 ternary complex formation in hypoxic Hspg2

D3/D3
mice LACE assay, with the addition of both chimeric FGFR1 and FGF2 on wild-type hypoxic lung sections, detected widespread binding of 
Figure 3 Increased perlecan expression in hypoxia-induced PH. (A)
Relative quantification of perlecan mRNA in whole lung homogenates. A significant increase was seen in both genotypes following 3.5 days of hypoxia. The data were normalized to age-matched, wild-type normoxic controls. b2-microglobulin was used as a reference gene (n ¼ 5; *P , 0.05 by two-way ANOVA with Bonferroni's multiple comparisons test). (B and C) Immunohistochemistry staining for perlecan core protein (red) in intra-acinar pulmonary vessels of wild-type mice under normoxia (B) and after 4 weeks of hypoxia (C ) showed perlecan accumulation in basement membranes of hypoxic vessels. White arrowheads indicate the location of perlecan staining.
FGFR1. Corresponding signals were significantly reduced on Hspg2
hypoxic lung sections, which suggested that perlecan HS contributes to FGFR1 binding. This was confirmed as heparinase III treatment of wild-type lung sections nearly abolished the binding of FGFR1 ( Figure 5C ). Further experiments with added chimeric FGFR1 and no FGF2 to lung sections yielded no signal. This indicates that both FGF2 and perlecan HS are required for ternary complex formation with FGFR1 (data not shown). The above findings could be replicated on hypoxia-treated PASMC cultures. Addition of FGF2, but with a lack of HS as in the Hspg2 D3/D3 or by heparinase III treatment of the wild type, resulted in poor binding of FGFR1 ( Figure 5D ).
Attenuated hypoxia-induced increase in FGFR1 protein and FGFR1 phosphorylation
Following 3.5 days of hypoxia, a significant and equivalent increase in FGFR1 mRNA expression was observed in both Hspg2 D3/D3 and wildtype lungs ( Figure 6A ), whereas western blot demonstrated a significant increase in FGFR1 protein only in the wild type ( Figure 6B and C) . In addition, there was an increased level of phosphorylated FGFR1 in both Hspg2 D3/D3 and wild-type lungs, although significantly less in Hspg2
( Figure 6B and D) . These findings indicate that perlecan HS is required for increased levels of FGFR1 protein and for FGFR1 phosphorylation. Analysis of PDGFRb protein levels under the same conditions as above revealed no differences between Hspg2 D3/D3 and wild type (see Supplementary material online, Figure S1 ).
Abrogated hypoxia-induced increase in FGF2 mRNA and decreased FGF2 protein
Following 4 weeks of hypoxia, FGF2 mRNA expression in wild-type lungs was significantly increased compared with normoxic controls. This increase was absent in Hspg2 D3/D3 lungs, where instead a trend of gradual decrease in FGF2 mRNA was observed ( Figure 6E ). Further analysis with western blot showed that the level of high-molecular-weight FGF2 protein was significantly decreased in Hspg2
, but remained unchanged in the wild type ( Figure 6F and G). There were no significant changes in low-molecular-weight FGF2 protein ( Figure 6F and G).
Selective FGFR1 inhibition reduces PASMC proliferation
To determine the role of FGFR1 for PASMC growth, a selective FGFR1 inhibitor 27 was used in vitro. A dose of PD166866 (1 mM) significantly inhibited FGF-2-induced wild-type PASMC proliferation both in normoxia (data not shown) and in hypoxia ( Figure 7A) . To confirm the effect of the inhibitor on FGFR1 phosphorylation, cells were pretreated with PD166866 2 h prior to FGF-2 stimulation and cell lysates were collected 15 min after FGF-2 stimulation for western blot analysis ( Figure 7A) . At higher concentrations, up to 10 mM, PD166866 inhibited 20% FBS-stimulated PASMC proliferation ( Figure 7B) . A pan-FGFR inhibitor, SU5402, was also tested. A dose of SU5402 (10 mM) significantly reduced FGF2-induced PASMC proliferation, but had no effect on 20% FBS-stimulated PASMCs (data not shown).
Reduced proliferation and increased adhesion in vitro
PASMC proliferation was studied in vitro. In normoxia (20% O 2 and 5% CO 2 ) and hypoxia (1% O 2 and 5% CO 2 ), both Hspg2 D3/D3 and wild type showed a significant and equivalent increase in DNA synthesis and cell numbers after stimulation with PDGF-B and FGF2 ( Figure 7C , data not shown for normoxic conditions). Stimulation with 20% fetal bovine serum under hypoxic conditions also resulted in a significant increase in DNA synthesis for both wild-type and Hspg2 D3/D3 PASMCs, but the increase was significantly smaller in Hspg2 D3/D3 ( Figure 7C ).
Altered cell adhesion was analysed as this may affect cell proliferation. PASMCs of Hspg2 D3/D3 displayed a significantly increased adhesion to fibronectin as well as at baseline, without any coating protein.
Adhesion to collagen IV or laminin was similar between Hspg2 D3/D3 and wild type ( Figure 7D ).
Discussion
Perlecan is a highly conserved basement membrane HS proteoglycan with diverse biological roles. 21 The negatively charged HS chains can sequester growth factors and thereby restrict their range of action, 24 but they may also serve as co-receptors to stabilize the growth factor -receptor complex for signalling. 28 The intact perlecan molecule is pro-angiogenic, 29 whereas a cleavage product from the C-terminal of the core protein (endorepellin) is anti-angiogenic. 30 In this study, we show that perlecan HS deficiency not only leads to a pulmonary arborization defect and loss of pericytes, but also attenuates hypoxia-induced PH accompanied by reduced vascular remodelling and less right ventricular hypertrophy. FGF2, a prototype HS/heparin-binding growth factor, has been reported to be elevated in patients with pulmonary arterial hypertension, 31 in monocrotaline-treated rats, 11 and in lambs with shuntinduced PH. 32 FGF2-siRNA and pharmacological FGFR inhibition have also been shown to reverse monocrotaline-induced PH in rats. 11 Additionally, our data here show that the FGF2/FGFR1 signalling pathway is involved in PH in mice. Hypoxia induces a significant increase in FGFR1 mRNA, protein level, and receptor phosphorylation in wild-type lungs. We have also observed a significant increase in FGF2 mRNA after 4 weeks of hypoxia in wild-type lungs. In contrast, in a previous study, no increase in FGF2 mRNA was observed in lasermicrodissected intrapulmonary arteries from Balb/cAnNCrlBR mice exposed to chronic hypoxia. The discrepancy between our findings may be explained by differences in mouse strain and methodology. On the protein level, our immunohistochemistry results showed that FGF2 is located predominantly in vessels in hypoxic lungs. We could, however, not demonstrate any significant increase in FGF2 protein in whole lung homogenates following hypoxic treatment.
In this study, we have found up-regulation of whole lung perlecan mRNA following 3.5 days of hypoxia and perlecan accumulation in the vascular basement membrane in response to chronic hypoxia. To our knowledge, this is the first report to show increased perlecan in hypoxia-induced PH. We also demonstrate that perlecan co-localizes with FGF2 in pulmonary arteries, and significantly reduced HS -FGF2 -FGFR1 ternary complex formation in Hspg2 D3/D3 lungs. This suggests that perlecan HS mediates FGF2 -FGFR1 interaction. This finding is in agreement with a previous report in which perlecan HS facilitates FGF2 signalling in the neointima of rat kidney allografts. 34 A study on human coronary artery SMCs also showed that perlecan HS promotes FGF2 signalling through ternary complex formation between FGF2 and FGFR1. 15 We speculate that perlecan HS serves as a co-receptor for FGFR1 or prevents FGFR1 proteolysis by ternary complex formation. The inability of Hspg2 D3/D3 mice to increase the FGFR1 protein level and phosphorylation in response to hypoxia may, in part, explain the observed reduction in PASMC proliferation and attenuated vascular remodelling. In addition, our results show significantly reduced HMW FGF2 following hypoxia in Hspg2 D3/D3 lungs.
Apart from being regulated by perlecan HS, HMW FGF2 is also known to be induced by PDGF-B in SMCs, 35 and has been shown to become pro-proliferative after thrombin cleavage. 36 HMW FGF2 can be found extracellularly and has been linked to myocardial hypertrophy. 37 Little is known regarding the role of HMW FGF2 in hypoxic PH. More studies will be needed to clarify its function. Here, we have demonstrated that perlecan HS deficiency leads to an arborization defect seen by angiography and to a reduction of a-SMA-positive cells in pulmonary vessels with a diameter of 20 -40 mm. In the embryo, pulmonary vascular development involves sprouting angiogenesis as well as vasculogenesis. 38 These processes are regulated by growth factors like VEGF, and also FGF2. 39 A regulatory role for perlecan in FGF2 signalling and angiogenesis is supported by a study by Gustafsson et al., where addition of FGF2 but not VEGF was shown to rescue defective angiogenesis in perlecan-null embryoid bodies. 40 Our LACE assay data emphasize the critical role of perlecan HS for the HS -FGF2 -FGFR1 ternary complex formation and is supported by our previous study, where FGF2 binding to the extracellular matrix from Hspg2 D3/D3 SMCs was significantly reduced. 24 The loss of pericyte coverage and defective arborization in Hspg2 D3/D3 mice may be a result of defective FGF2 storage and positioning in the matrix. The reduced recruitment of pericytes seen with perlecan HS deficiency may also contribute to reduced development of hypoxic PH. Ricard et al. recently published a study, showing that recruitment of pericytes is of importance for the development of PH. The number of pericytes substantially increases in distal pulmonary arteries of patients with idiopathic pulmonary arterial hypertension. The data also suggested that this increase is mediated by FGF2. 12 Other growth factors may, however, also be of importance. PDGF-B, dependent on its retention motif that mediates binding to HS, has been shown to recruit pericytes to the vascular wall. Defective pericyte attachment in microvessels has been demonstrated in retention motif knockout mice (Pdgfb ret/ret ), 41 and a similar phenotype has been reported in mice with defective N-sulfation of HS. 42 It is therefore quite possible that perlecan HS deficiency also affects PDGF storage in the extracellular matrix. Our findings of equivalent levels of PDGFRb in Hspg2
and wild type do not exclude this possibility. Here, we have shown that perlecan HS deficiency inhibits PASMC proliferation. However, the findings from systemic arteries would predict perlecan to be anti-proliferative rather than pro-proliferative. 43, 44 We previously reported that Hspg2 D3/D3 mice develop increased intimal hyperplasia in carotid arteries after flow cessation, and the role of perlecan HS in the carotid is likely to be to bind and sequester FGF2 and thereby limit signalling. 24 Because there is variation of glycanation of perlecan HS in different cell types and different sulfation patterns can modulate FGF2 signalling in different ways, 15, 34, 45 it is highly possible that HS chains in pulmonary arteries have a different glycan structure compared with those in systemic arteries. The relative amount of endothelial-derived vs. SMC-derived perlecan is also most likely higher in the intra-acinar pulmonary vessels compared with the carotid artery. These two sources of HS have recently been shown to have different signalling properties. 14 Moreover, our data show significantly reduced Hspg2 D3/D3 PASMC proliferation in vitro in hypoxia, but not in normoxia. This finding suggests that the sulfation pattern of HS may be subjected to further modification after hypoxia exposure.
Other types of cell -matrix interactions may also be of importance.
Hspg2
D3/D3 PASMCs adhere more strongly to fibronectin, indicating that perlecan HS may be involved in the regulation of the adhesive strength of cells to the extracellular matrix. Adhesive strength has been shown to affect cell proliferation and may in part explain the different response in proliferation between wild-type and Hspg2
D3/D3
cells in this study. Our study has its limitations. The data presented only demonstrates that basement membrane perlecan HS regulates FGF2 -FGFR1 interaction at the extracellular level. The effect of perlecan HS deficiency on pathways downstream of FGF2-FGFR1 awaits further investigation. Interactions between other FGFs and FGF receptors are also likely to be altered in Hspg2 D3/D3 mice, and the impacts of perlecan HS deficiency on other heparin/HS-binding factors such as PDGF, VEGF, Wnt, and BMP need to be addressed in future studies. FGF2/FGFR1 is an example of the importance of growth factor -proteoglycan interactions in hypoxia-induced PH.
In conclusion, perlecan HS in the basement membrane is important for normal vascular arborization and recruitment of pericytes to pulmonary vessels. Perlecan HS deficiency attenuates hypoxia-induced PH, where the underlying mechanisms involve impaired FGF2/FGFR1 ternary complex formation and receptor phosphorylation, inhibition of PASMC growth, and altered cell -matrix interactions.
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Supplementary material is available at Cardiovascular Research online.
